A Randomized, Balanced, Phase 1/2A, Multiple-dose, Open-label, Two-treatment, Two-period, Two-sequence, Crossover, Relative Bioavailability Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

The goal of this clinical trial is to assess the safety and effects of a crystallized form of lithium, AL001, when compared to commonly used lithium carbonate in individuals diagnosed with bipolar I disorder. The main questions this study aims to answer are:
* How safe is AL001 when compared to lithium carbonate?
* How is AL001 broken down in the brain and body compared to lithium carbonate?
Participants will be asked to:
* Take both the study drug (AL001) and lithium carbonate each for a period of 14 days.
* Stay overnight at MGH's research unit for two separate 2-week periods.
* Participate in two separate 24 hour periods of multiple MRIs and blood draws.

开始日期2026-05-11

申办/合作机构

Alzamend Neuro, Inc.

[+1]

ChiCTR2600121292

/ Not yet recruiting临床1/2期IIT

An international multicenter clinical trial on the prevention and treatment of radiation-induced oral mucositis and taste disorders with lithium salt water gel

开始日期2026-03-07

申办/合作机构

四川大学华西口腔医院

ChiCTR2500113193

/ Suspended临床2期IIT

Toripalimab in combination with chemotherapy and lithium carbonate for first-line treatment of extensive-stage small cell lung cancer in stage Ib/II clinical research

开始日期2025-09-30

申办/合作机构-

100 项与碳酸锂相关的临床结果

登录后查看更多信息

100 项与碳酸锂相关的转化医学

登录后查看更多信息

100 项与碳酸锂相关的专利（医药）

登录后查看更多信息

17,669

项与碳酸锂相关的文献（医药）

2026-11-01·JOURNAL OF AFFECTIVE DISORDERS

Characterization and clinical prioritization of neurotoxicity-related safety signals associated with lithium and haloperidol co-administration: A pharmacovigilance study based on FAERS

Article

作者: Xiong, Jianwen ; Wu, Xiaopeng ; Zhang, Shuang ; Zhou, Chaoxiong ; Zheng, Liyun

OBJECTIVE:

The concurrent use of lithium carbonate and haloperidol is common in psychiatric practice, yet it remains unclear which neurotoxicity-related adverse events are specific to the combination rather than to either agent alone. This study aimed to identify and prioritize the neurotoxicity-related manifestations potentially associated with this drug combination.

METHODS:

Neurological and psychiatric adverse event reports were extracted from FAERS covering Q1 2004 through Q4 2025 and stratified into lithium reports without haloperidol, haloperidol reports without lithium, and combination co-administration reports. Drug-event-pair-based reporting odds ratios were used for signal estimation, while report-level dual-comparator screening was used to retain co-administration-associated signals. Retained signals were ranked using a semi-quantitative clinical prioritization system. Sensitivity analysis under a stricter exposure definition assessed robustness.

RESULTS:

A total of 9745 target reports were included (combination co-administration: 429; lithium without haloperidol: 3688; haloperidol without lithium: 5628). Twenty-eight reporting signals were more frequently reported with co-administration than with reports involving either target drug without the other in the main analysis, with 14 retained after sensitivity analysis. Neuroleptic malignant syndrome, neurotoxicity, encephalopathy, and delirium remained moderate-priority signals in both analyses.

CONCLUSION:

Neurotoxicity, neuroleptic malignant syndrome, encephalopathy, and delirium warrant prioritized clinical attention during lithium carbonate and haloperidol co-administration. These hypothesis-generating findings support targeted neurological and neuropsychiatric monitoring for patients receiving this combination.

2026-09-01·BIOSENSORS & BIOELECTRONICS

Highly specific aptamer-based structure-switching sensor for detection of the smallest alkali metal ion Li+ in serum

Article

作者: Yin, Jiye ; Zhou, Boting ; Yu, Yujia ; Wang, Jin ; Guo, Chengxian ; Lei, Hongtao ; Tan, Hongyi ; Yang, Chao

Lithium carbonate, a frontline drug for bipolar disorder (BD), requires strict therapeutic drug monitoring (TDM) due to its narrow therapeutic window (0.6-1.2 mM). Existing methods like inductively coupled plasma mass spectrometry (ICP-MS) and ion-selective electrodes (ISE) struggle to balance point-of-care testing (POCT) demands with interference in complex matrices. Here, we isolated a highly specific Li⁺ DNA aptamer (Li-1) via a Capture-SELEX strategy and constructed a sensitive structure-switching fluorescent sensor. Isothermal titration calorimetry (ITC) and circular dichroism (CD) spectroscopy were utilized to perform thermodynamic and structural analyses of its molecular recognition process, revealing that the binding of Li-1 to Li⁺ is dominated by an "enthalpy-driven" conformational rearrangement. Based on a 5-carboxyfluorescein (FAM)-labeled DNA strand displacement strategy, the established sensor achieved a dynamic linear response of 6.2 - 60 μM with a limit of detection (LOD) of 1.8 μM. It exhibited no obvious cross-recognition to Na⁺, K⁺, Ca²⁺, and Mg²⁺. The spiked recovery rates ranged from 88.76% to 102.33%. In double-blind tests of clinical BD patient serum, the method showed strong statistical agreement (Pearson's r > 0.92) with the clinical gold standard ICP-MS. This work develops a DNA aptamer targeting the smallest alkali metal ion, Li⁺, providing a highly specific and sensitive method for POCT blood lithium monitoring in psychiatric practice.

2026-08-01·The Lancet Psychiatry

Brain lithium temporospatial kinetics in bipolar disorder: a repeated-measures 7Li MRI study of dosing regimens in Germany

Article

作者: Edelmann, Katinka ; Bauer, Michael ; Werner, Annett ; Kavanagh, Oisín ; Boumezbeur, Fawzi ; Hall, Gerard ; Ritter, Philipp ; Cousins, David Andrew ; Thelwall, Peter Edward

BACKGROUND:

Lithium remains a first-line treatment for bipolar disorder, but practice varies regarding dosing frequency. Although once-daily and twice-daily regimens are similarly effective, they produce serum lithium profiles that differ over the day, and whether greater fluctuations with once-daily dosing are attenuated in the brain is unclear. The aim of this study was to evaluate whether brain lithium profiles differed across the day with once-daily versus twice-daily dosing regimens.

METHODS:

In this repeated-measures, cross-sectional imaging study, euthymic individuals (aged 18-50 years) with bipolar disorder type I or II receiving stable lithium carbonate treatment were recruited at four psychiatric outpatient departments in Dresden, Germany. In the week before assessment, participants received lithium at 2000 h (full once-daily dose or evening dose of the twice-daily regimen) and 0800 (twice-daily regimen only; withheld until after the 0800 h sampling on assessment day). The core assessment was a 1-day protocol in which participants underwent three consecutive ⁷Li MRI scans and matched serum sampling over a 10-h period (0800, 1400, and 1800h). Whole-brain lithium measurements across timepoints were compared according to regimen using the brain observable lithium threshold region-of-interest approach. Secondary analyses modelled tissue-specific profiles, derived from the Newcastle lithium image voxel evaluation pipeline, and examined the relationship between serum lithium concentration and brain ⁷Li MRI signal intensity using repeated-measures ANOVA, linear mixed-effects models, and population pharmacokinetics. This study was informed by people with lived experience of bipolar disorder and long-term lithium treatment through patient and public involvement and engagement activities.

FINDINGS:

Between April 19, 2022, and Dec 9, 2023, 44 eligible participants were recruited, of whom three withdrew before assessment. Therefore, 41 euthymic individuals (all White European; 21 [51%] female and 20 [49%] male; mean age 39·2 years [SD 9·8]) with bipolar disorder receiving stable lithium carbonate treatment (20 in the once-daily dosing group and 21 in the twice-daily dosing group) were evaluated. At 12 h post dose (0800 h), brain ⁷Li MRI signal intensity and serum lithium concentrations were equivalent across regimens. In the once-daily group, serum lithium declined across the day, whereas in the twice-daily group it increased after the morning dose and then decreased. Brain ⁷Li MRI signal intensity closely mirrored these regimen-specific serum profiles. Brain ⁷Li MRI signal intensity was higher in white matter than grey matter in both regimens and brain-to-serum ratios indicated more rapid equilibration in grey matter compared with cerebrospinal fluid and white matter.

INTERPRETATION:

Brain lithium concentrations followed serum concentrations closely across the day but aligned between regimens at the standard 12-h post-dose sampling timepoint. These findings directly inform ongoing discussions about the applicability of a common reference range across regimens. The difference in brain and serum profiles of lithium with once-daily and twice-daily dosing might inform regimen selection and therapeutic monitoring strategies in clinical practice.

FUNDING:

Baszucki Brain Research Foundation and Deutsche Forschungsgemeinschaft (German Research Foundation).

200

项与碳酸锂相关的新闻（医药）

2026-08-26

·ZAKER

三大指数小幅收跌 AI 算力硬件及医药股逆势走强

财联社 8 月 25 日讯（编辑胡家荣）港股三大指数集体收跌。截至收盘，恒生指数跌 0.02%，报收 25511.10 点；科技指数跌 0.12%，报收 4588.54 点；国企指数跌 0.31%，报收 8445.37 点。今日市场从市场表现来看，PCB、存储芯片及医药 CXO 相关个股表现活跃，其中多只龙头标的领涨；而黄金及锂电池股则承压回调。算力硬件迭代加码建滔系业绩利好提振截至收盘，建滔积层板 ( 01888.HK ) 涨 13.79%，建滔集团 ( 00148.HK ) 涨 11.78%，大族数控 ( 03200.HK ) 涨 7.29%。消息方面，OpenAI 基础设施负责人 Uday Ruddarraju 日前透露，首批英伟达 Vera Rubin 机架已部署完成并运行公司训练栈，标志着下一代前沿 AI 预训练算力扩容迈出实质性一步。机构称英伟达 Vera Rubin 整机平台的落地将带动 AI 服务器硬件全面升级，显著提升高端 PCB 的技术壁垒。结合海外头部云厂商持续加大算力资本开支，高端 PCB 的中长期需求具备坚实支撑，行业景气度有望延续。建滔积层板公布上半年归母净利润同比增长 209%。花旗称，鉴于公司 7 月份盈利水平略强于预期，将 2026 至 2028 年盈利预测上调 9% – 10%，并将目标价上调至 95 港元。巨头 AI 资本开支可观兆易创新涨近 5%截至收盘，澜起科技 ( 06809.HK ) 涨 4.96%，兆易创新 ( 03986.HK ) 涨 4.93%。消息方面，高盛在最新研报中指出，全球 AI 热潮正驱动国内新一轮半导体投资。据高盛测算，阿里巴巴、腾讯、字节跳动和百度四家科技巨头在 2026 年的 AI 资本支出总额预计将达 1020 亿美元左右，这将为国内半导体产业链的大规模产能建设提供强劲拉动。投融资回暖与 AI 技术渗透凯莱英涨超 16%截至收盘，凯莱英 ( 06821.HK ) 涨 16.02%，金斯瑞生物科技 ( 01548.HK ) 涨 7.42%，药明生物 ( 02269.HK ) 涨 7.41%。消息方面，全球生物医药投融资逐步筑底回暖，带动创新药研发投入重新提速，海内外 CXO 龙头企业的订单与业绩正相继兑现。另一方面，AI 技术正深度渗透至靶点挖掘、分子生成及工艺优化等药物研发全流程，显著缩短研发周期并提升早期药物发现效率，推动行业长远景气度持续上行。月内高位累涨后遇期权大单异动灵宝黄金跌超 6%截至收盘，灵宝黄金 ( 03330.HK ) 跌 6.47%，招金矿业 ( 01818.HK ) 跌 5.05%，山东黄金 ( 01787.HK ) 跌 3.51%。消息方面，本月黄金在美债收益率与实际利率同步走高的环境下依然展现出强劲韧性，累计涨幅超 15%，有望创下 2008 年以来最佳单月表现。然而，周一美国期权市场出现规模罕见的黄金 ETF 大单交易，表明市场资金在快速拉升后开始押注短期回调。此外，美国财政部高级官员透露，财政部正利用一般账户资金支持国债回购。当前贝森特已将 TGA 余额扩大至约 9500 亿美元，此前财政部意外将国债回购规模翻倍，但市场对其资金实际动用能力存疑，导致该举措对美债收益率的压制效果相对短暂。碳酸锂期货主连走弱赣锋锂业跌近 5%截至收盘，天齐锂业 ( 09696.HK ) 跌 4.87%，赣锋锂业 ( 01772.HK ) 跌 4.65%，宁德时代 ( 03750.HK ) 跌 2.74%。消息方面，受上游原材料价格波动影响，碳酸锂主力合约走弱，收盘下跌 6.09%，报元 150280/ 吨，传导至现货及二级市场，拖累锂电龙头股走势。个股异动海清智元涨超 10% 下月有望进入港股通名单海清智元 ( 01392.HK ) 涨 10.56%，报收 27.42 港元。消息方面，恒生指数公司此前公布季度检讨结果，海清智元获纳入恒生综合指数，相关变动将于 9 月 4 日收市后实施，并于 9 月 7 日起生效。市场预计，基于公司在市值与流动性等多项指标上均已达标，届时有望随着沪深交易所的同步调整被正式调入港股通名单。阿里巴巴盘中一度涨超 2% 机构称配股集资摊薄效应有限阿里巴巴 -W ( 09988.HK ) 涨 1.51%，盘中一度涨超 2%。大和最新研报指出，公司拟配售 7.1 亿股新股，筹集资金 800 亿港元。本次每股配售价 112.7 港元 ( 相当于每份 ADR115 美元 ) ，较 H 股及 ADR 最新收盘价折让 8.4% 与 3.6%。该行认为本次配股带来的摊薄效应相对有限，且募集资金净额将全数投入全栈 AI 能力建设及基础设施扩容，有利于强化长期 AI 算力竞争壁垒。

2026-08-25

·搜狐新闻

港股收盘 | 三大指数小幅收跌 AI算力硬件及医药股逆势走强

转自：财联社财联社8月25日讯（编辑胡家荣）港股三大指数集体收跌。截至收盘，恒生指数跌0.02%，报收25511.10点；科技指数跌0.12%，报收4588.54点；国企指数跌0.31%，报收8445.37点。今日市场从市场表现来看，PCB、存储芯片及医药CXO相关个股表现活跃，其中多只龙头标的领涨；而黄金及锂电池股则承压回调。算力硬件迭代加码建滔系业绩利好提振截至收盘，建滔积层板(01888.HK)涨13.79%，建滔集团(00148.HK)涨11.78%，大族数控(03200.HK)涨7.29%。消息方面，OpenAI基础设施负责人Uday Ruddarraju日前透露，首批英伟达Vera Rubin机架已部署完成并运行公司训练栈，标志着下一代前沿AI预训练算力扩容迈出实质性一步。机构称英伟达Vera Rubin整机平台的落地将带动AI服务器硬件全面升级，显著提升高端PCB的技术壁垒。结合海外头部云厂商持续加大算力资本开支，高端PCB的中长期需求具备坚实支撑，行业景气度有望延续。建滔积层板公布上半年归母净利润同比增长209%。花旗称，鉴于公司7月份盈利水平略强于预期，将2026至2028年盈利预测上调9%–10%，并将目标价上调至95港元。巨头AI资本开支可观兆易创新涨近5% 截至收盘，澜起科技(06809.HK)涨4.96%，兆易创新(03986.HK)涨4.93%。消息方面，高盛在最新研报中指出，全球AI热潮正驱动国内新一轮半导体投资。据高盛测算，阿里巴巴、腾讯、字节跳动和百度四家科技巨头在2026年的AI资本支出总额预计将达1020亿美元左右，这将为国内半导体产业链的大规模产能建设提供强劲拉动。投融资回暖与AI技术渗透凯莱英涨超16% 截至收盘，凯莱英(06821.HK)涨16.02%，金斯瑞生物科技(01548.HK)涨7.42%，药明生物(02269.HK)涨7.41%。消息方面，全球生物医药投融资逐步筑底回暖，带动创新药研发投入重新提速，海内外CXO龙头企业的订单与业绩正相继兑现。另一方面，AI技术正深度渗透至靶点挖掘、分子生成及工艺优化等药物研发全流程，显著缩短研发周期并提升早期药物发现效率，推动行业长远景气度持续上行。月内高位累涨后遇期权大单异动灵宝黄金跌超6% 截至收盘，灵宝黄金(03330.HK)跌6.47%，招金矿业(01818.HK)跌5.05%，山东黄金(01787.HK)跌3.51%。消息方面，本月黄金在美债收益率与实际利率同步走高的环境下依然展现出强劲韧性，累计涨幅超15%，有望创下2008年以来最佳单月表现。然而，周一美国期权市场出现规模罕见的黄金ETF大单交易，表明市场资金在快速拉升后开始押注短期回调。此外，美国财政部高级官员透露，财政部正利用一般账户资金支持国债回购。当前贝森特已将TGA余额扩大至约9500亿美元，此前财政部意外将国债回购规模翻倍，但市场对其资金实际动用能力存疑，导致该举措对美债收益率的压制效果相对短暂。碳酸锂期货主连走弱赣锋锂业跌近5% 截至收盘，天齐锂业(09696.HK)跌4.87%，赣锋锂业(01772.HK)跌4.65%，宁德时代(03750.HK)跌2.74%。消息方面，受上游原材料价格波动影响，碳酸锂主力合约走弱，收盘下跌6.09%，报元150280/吨，传导至现货及二级市场，拖累锂电龙头股走势。个股异动海清智元涨超10% 下月有望进入港股通名单海清智元(01392.HK)涨10.56%，报收27.42港元。消息方面，恒生指数公司此前公布季度检讨结果，海清智元获纳入恒生综合指数，相关变动将于9月4日收市后实施，并于9月7日起生效。市场预计，基于公司在市值与流动性等多项指标上均已达标，届时有望随着沪深交易所的同步调整被正式调入港股通名单。阿里巴巴盘中一度涨超2% 机构称配股集资摊薄效应有限阿里巴巴-W(09988.HK)涨1.51%，盘中一度涨超2%。大和最新研报指出，公司拟配售7.1亿股新股，筹集资金800亿港元。本次每股配售价112.7港元(相当于每份ADR115美元)，较H股及ADR最新收盘价折让8.4%与3.6%。该行认为本次配股带来的摊薄效应相对有限，且募集资金净额将全数投入全栈AI能力建设及基础设施扩容，有利于强化长期AI算力竞争壁垒。（财联社胡家荣）返回搜狐，查看更多

2026-08-25

·网易号

港股收盘 | 三大指数小幅收跌 AI算力硬件及医药股逆势走强

财联社8月25日讯（编辑胡家荣）港股三大指数集体收跌。截至收盘，恒生指数跌0.02%，报收25511.10点；科技指数跌0.12%，报收4588.54点；国企指数跌0.31%，报收8445.37点。今日市场从市场表现来看，PCB、存储芯片及医药CXO相关个股表现活跃，其中多只龙头标的领涨；而黄金及锂电池股则承压回调。算力硬件迭代加码建滔系业绩利好提振截至收盘，建滔积层板(01888.HK)涨13.79%，建滔集团(00148.HK)涨11.78%，大族数控(03200.HK)涨7.29%。消息方面，OpenAI基础设施负责人Uday Ruddarraju日前透露，首批英伟达Vera Rubin机架已部署完成并运行公司训练栈，标志着下一代前沿AI预训练算力扩容迈出实质性一步。机构称英伟达Vera Rubin整机平台的落地将带动AI服务器硬件全面升级，显著提升高端PCB的技术壁垒。结合海外头部云厂商持续加大算力资本开支，高端PCB的中长期需求具备坚实支撑，行业景气度有望延续。建滔积层板公布上半年归母净利润同比增长209%。花旗称，鉴于公司7月份盈利水平略强于预期，将2026至2028年盈利预测上调9%–10%，并将目标价上调至95港元。巨头AI资本开支可观兆易创新涨近5%截至收盘，澜起科技(06809.HK)涨4.96%，兆易创新(03986.HK)涨4.93%。消息方面，高盛在最新研报中指出，全球AI热潮正驱动国内新一轮半导体投资。据高盛测算，阿里巴巴、腾讯、字节跳动和百度四家科技巨头在2026年的AI资本支出总额预计将达1020亿美元左右，这将为国内半导体产业链的大规模产能建设提供强劲拉动。投融资回暖与AI技术渗透凯莱英涨超16%截至收盘，凯莱英(06821.HK)涨16.02%，金斯瑞生物科技(01548.HK)涨7.42%，药明生物(02269.HK)涨7.41%。消息方面，全球生物医药投融资逐步筑底回暖，带动创新药研发投入重新提速，海内外CXO龙头企业的订单与业绩正相继兑现。另一方面，AI技术正深度渗透至靶点挖掘、分子生成及工艺优化等药物研发全流程，显著缩短研发周期并提升早期药物发现效率，推动行业长远景气度持续上行。月内高位累涨后遇期权大单异动灵宝黄金跌超6%截至收盘，灵宝黄金(03330.HK)跌6.47%，招金矿业(01818.HK)跌5.05%，山东黄金(01787.HK)跌3.51%。消息方面，本月黄金在美债收益率与实际利率同步走高的环境下依然展现出强劲韧性，累计涨幅超15%，有望创下2008年以来最佳单月表现。然而，周一美国期权市场出现规模罕见的黄金ETF大单交易，表明市场资金在快速拉升后开始押注短期回调。此外，美国财政部高级官员透露，财政部正利用一般账户资金支持国债回购。当前贝森特已将TGA余额扩大至约9500亿美元，此前财政部意外将国债回购规模翻倍，但市场对其资金实际动用能力存疑，导致该举措对美债收益率的压制效果相对短暂。碳酸锂期货主连走弱赣锋锂业跌近5%截至收盘，天齐锂业(09696.HK)跌4.87%，赣锋锂业(01772.HK)跌4.65%，宁德时代(03750.HK)跌2.74%。消息方面，受上游原材料价格波动影响，碳酸锂主力合约走弱，收盘下跌6.09%，报元150280/吨，传导至现货及二级市场，拖累锂电龙头股走势。个股异动海清智元涨超10% 下月有望进入港股通名单海清智元(01392.HK)涨10.56%，报收27.42港元。消息方面，恒生指数公司此前公布季度检讨结果，海清智元获纳入恒生综合指数，相关变动将于9月4日收市后实施，并于9月7日起生效。市场预计，基于公司在市值与流动性等多项指标上均已达标，届时有望随着沪深交易所的同步调整被正式调入港股通名单。阿里巴巴盘中一度涨超2% 机构称配股集资摊薄效应有限阿里巴巴-W(09988.HK)涨1.51%，盘中一度涨超2%。大和最新研报指出，公司拟配售7.1亿股新股，筹集资金800亿港元。本次每股配售价112.7港元(相当于每份ADR115美元)，较H股及ADR最新收盘价折让8.4%与3.6%。该行认为本次配股带来的摊薄效应相对有限，且募集资金净额将全数投入全栈AI能力建设及基础设施扩容，有利于强化长期AI算力竞争壁垒。（财联社胡家荣）

100 项与碳酸锂相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00801	碳酸锂	N05AN01	DB14509

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
躁郁症1型	美国	Hikma Pharmaceuticals USA, Inc.	1982-01-29
躁郁症	美国	Pfizer Inc.	1970-04-06
躁郁症	美国	Solvay Pharmaceuticals, Inc.	1970-04-06
分裂情感性障碍	美国	Solvay Pharmaceuticals, Inc.	1970-04-06
分裂情感性障碍	美国	Pfizer Inc.	1970-04-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
克莱恩-莱文综合征	临床前	欧盟	Laboratoires Delbert SAS	2023-08-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03185208 (Pubmed \| JAMA Neurol)	临床2期	轻度认知障碍	80	Lithium carbonate	夢廠夢遞鏇糧醖繭願鑰(範窪獵艱淵簾繭淵鬱醖) = 鏇製鹽網積蓋鏇遞遞繭繭廠選憲衊範餘鹽鹽鹽 (膚構壓餘襯糧餘糧糧鏇 ) 更多	积极	2026-04-01
NCT03185208 (Pubmed \| JAMA Neurol)	临床2期	轻度认知障碍	80	Placebo	夢廠夢遞鏇糧醖繭願鑰(範窪獵艱淵簾繭淵鬱醖) = 簾製願簾憲繭憲積餘製繭廠選憲衊範餘鹽鹽鹽 (膚構壓餘襯糧餘糧糧鏇 ) 更多	积极	2026-04-01
NCT03185208 (LATTICE, CTgov)	临床4期	阿尔茨海默症 \| 轻度认知障碍	83	Lithium Carbonate (Lithium Carbonate)	窪襯顧願築蓋蓋齋夢繭(鬱衊壓選鏇襯夢願鑰積) = 範構醖鏇醖襯膚鏇範遞憲窪顧廠獵餘齋選簾憲 (夢願積餘膚鏇窪獵衊齋, 4.0) 更多	-	2025-09-11
NCT03185208 (LATTICE, CTgov)	临床4期	阿尔茨海默症 \| 轻度认知障碍	83	Placebo oral capsule (Placebo)	窪襯顧願築蓋蓋齋夢繭(鬱衊壓選鏇襯夢願鑰積) = 糧醖簾獵蓋鑰窪鹽憲鹽憲窪顧廠獵餘齋選簾憲 (夢願積餘膚鏇窪獵衊齋, 4.6) 更多	-	2025-09-11
NCT02862210 (Lithium, CTgov)	临床2期	额颞痴呆	17	Lithium Carbonate (Lithium Carbonate)	繭齋鬱觸廠膚衊廠製鹹(廠壓積夢憲築製選製顧) = 繭餘蓋糧獵廠艱獵鑰夢醖鹽觸遞齋簾積網餘廠 (鏇襯醖餘網鹹膚鹹蓋鹹, 1.1) 更多	-	2025-02-03
NCT02862210 (Lithium, CTgov)	临床2期	额颞痴呆	17	Placebo (Placebo)	繭齋鬱觸廠膚衊廠製鹹(廠壓積夢憲築製選製顧) = 積膚鑰鏇選糧築製糧範醖鹽觸遞齋簾積網餘廠 (鏇襯醖餘網鹹膚鹹蓋鹹, 1.28) 更多	-	2025-02-03
NCT00961961 (CTgov)	临床4期	躁郁症 \| 躁郁症1型	177	Lithium Carbonate+Fluoxetine (Lithium Plus Fluoxetine Phase I)	夢淵襯觸襯窪膚範鬱淵 = 餘鹹淵衊齋繭鏇願窪鹽鑰顧艱壓艱衊範醖構構 (齋顧醖淵繭鏇築獵遞構, 齋網憲壓窪餘鬱築餘積 ~ 醖淵鏇鏇鬱獵鏇蓋網鏇) 更多	-	2020-10-19
NCT00961961 (CTgov)	临床4期	躁郁症 \| 躁郁症1型	177	Lithium / Placebo (Lithium Plus Placebo Phase I)	夢淵襯觸襯窪膚範鬱淵 = 艱範遞鏇選範壓膚鏇繭鑰顧艱壓艱衊範醖構構 (齋顧醖淵繭鏇築獵遞構, 憲選夢膚廠選壓窪襯憲 ~ 壓鏇蓋築淵獵淵壓範醖) 更多	-	2020-10-19
NCT02918097 (CTgov)	临床4期	躁郁症	78	Lithium Carbonate+risperidone+Nortriptyline+sertraline	觸遞衊鬱顧選壓夢衊鹽 = 廠選鬱膚獵鑰觸獵範餘衊壓獵網夢積範鏇蓋選 (淵繭壓築獵積觸鑰觸蓋, 繭鏇醖遞鏇窪鹽齋窪繭 ~ 繭顧衊蓋遞構廠襯衊遞) 更多	-	2020-10-14
NCT01820624 (Pubmed) 人工标引	临床1期	急性髓性白血病	9	lithium carbonate+tretinoin	窪蓋蓋鹽築艱鹽糧襯齋(願選餘蓋襯壓醖廠構衊) = 製獵積範齋壓獵壓遞衊窪壓製衊鹽製觸網齋積 (構構製淵蓋夢廠繭網壓 )	不佳	2020-03-10
NCT01553916 (CTgov)	临床1/2期	小细胞肺癌	19	Prophylactic cranial irradiation+Lithium Carbonate	膚選鑰範選廠網鑰廠襯 = 齋觸鏇壓蓋糧窪憲窪構憲製鏇膚網夢網鹽鹹製 (壓選廠衊醖願構網觸廠, 遞願顧齋鹽齋鏇鹹製醖 ~ 鹹網願簾衊衊壓鏇襯窪) 更多	-	2017-11-08
NCT00501540 (CTgov)	临床2期	神经内分泌肿瘤	15	Lithium Carbonate	鬱網蓋鑰積製窪鏇獵選 = 夢網糧憲獵網齋襯憲淵糧網觸醖憲願齋鹹淵獵 (鹽夢膚獵觸選膚醖廠網, 構衊築鹽膚願窪願網構 ~ 願鏇廠窪選觸遞膚糧夢) 更多	-	2017-05-03
NCT00408681 (GVHD, CTgov)	N/A	复发性边缘区淋巴瘤 \| 妊娠滋养细胞疾病 \| 成人急性髓性白血病 ... 更多	20	laboratory biomarker analysis+lithium carbonate	觸鬱遞簾鹹糧選衊餘構 = 艱鏇窪築餘鏇構選廠醖構積觸簾繭蓋窪鹽憲鬱 (廠獵鹽築遞鬱鑰餘鹹壓, 醖願觸選鑰積鏇膚淵網 ~ 鑰糧繭糧獵淵鬱簾範簾)	-	2017-01-20
NCT00582712 (CTgov)	临床2期	甲状腺髓样癌	5	Lithium carbonate	鏇壓選醖糧廠餘積醖繭(鬱遞餘蓋膚顧鏇膚廠鹽) = 齋蓋鹽淵鑰觸顧願齋齋獵築蓋憲艱選獵醖觸鏇 (糧鹹築膚壓窪鹹遞膚艱, 鑰鑰淵遞鏇鹽膚壓壓製 ~ 廠範糧夢繭夢繭膚願淵) 更多	-	2016-12-12